{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:23:02Z","timestamp":1722892982683},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T00:00:00Z","timestamp":1321488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1038\/hr.2011.178","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T07:10:10Z","timestamp":1321513810000},"page":"221-227","source":"Crossref","is-referenced-by-count":0,"title":["Optimal Combination of Effective ANtihypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial\u2014rationale, design and results of a pilot study in Japan"],"prefix":"10.1038","volume":"35","author":[{"name":"for the OCEAN Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kageyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,17]]},"reference":[{"key":"BFhr2011178_CR1","first-page":"3","volume":"32","author":"T Ogihara","year":"2009","unstructured":"Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, on behalf of the Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3\u2013107.","journal-title":"Hypertens Res"},{"key":"BFhr2011178_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, The National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206\u20131252.","journal-title":"Hypertension"},{"key":"BFhr2011178_CR3","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","volume":"21","author":"World Health Organization, International Society of Hypertension Writing Group;","year":"2003","unstructured":"World Health Organization, International Society of Hypertension Writing Group;. 2003 World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983\u20131992.","journal-title":"J Hypertens"},{"key":"BFhr2011178_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/pds.1609","volume":"17","author":"Y Kamijima","year":"2008","unstructured":"Kamijima Y, Ooba N, Yagame M, Samizo K, Shimodozono Y, Kageyama S, Horiguchi S, Nagai R, Kusunoki T, Kubota K . Hypertension management in diabetic patients: prescribing trends from 1999\u20132005 in three Japanese university hospitals. Pharmacoepidemiol Drug Saf 2008; 17: 904\u2013911.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"BFhr2011178_CR5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995\u20131003.","journal-title":"Lancet"},{"key":"BFhr2011178_CR6","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022\u20132031.","journal-title":"Lancet"},{"key":"BFhr2011178_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O\u2019Brien E, Ostergren J, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895\u2013906.","journal-title":"Lancet"},{"key":"BFhr2011178_CR8","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahl\u00f6f B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, for the Accomplish Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417\u20132428.","journal-title":"N Engl J Med"},{"key":"BFhr2011178_CR9","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2008.102","volume":"73","author":"GL Bakris","year":"2008","unstructured":"Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P, On behalf of the GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73: 1303\u20131309.","journal-title":"Kidney Int"},{"key":"BFhr2011178_CR10","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.","year":"2002","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981\u20132997.","journal-title":"JAMA"},{"key":"BFhr2011178_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(01)06411-X","volume":"358","author":"JA Staessen","year":"2001","unstructured":"Staessen JA, Wang J-G, Thijs L . Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305\u20131315.","journal-title":"Lancet"},{"key":"BFhr2011178_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1291\/hypres.25.175","volume":"25","author":"I Saito","year":"2002","unstructured":"Saito I, Kawabe H, Tsujioka M, Hirose H, Shibata H . Trends in pharmacologic management of hypertension in Japan one year after the publication of the JSH 2000 guidelines. Hypertens Res 2002; 25: 175\u2013178.","journal-title":"Hypertens Res"},{"key":"BFhr2011178_CR13","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1161\/01.STR.0000090348.52943.A2","volume":"34","author":"M Kubo","year":"2003","unstructured":"Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M . Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community. The Hisayama Study. Stroke 2003; 34: 2349\u20132354.","journal-title":"Stroke"},{"key":"BFhr2011178_CR14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/00004872-199610000-00013","volume":"14","author":"L Gong","year":"1996","unstructured":"Gong L, Zhang W, Zhu Y, Zhu J, collaborating centres in the Shanghai area, Kong D, Page V, Ghadirian P, LeLorier J, Hamet P . Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237\u20131245.","journal-title":"J Hypertens"},{"key":"BFhr2011178_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/00004872-199816120-00016","volume":"16","author":"L Liu","year":"1998","unstructured":"Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823\u20131829.","journal-title":"J Hypertens"},{"key":"BFhr2011178_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/08037059209077502","volume":"1","author":"L Hansson","year":"1992","unstructured":"Hansson L, Hedner T, Dahl\u00f6f B, Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992; 1: 113\u2013119.","journal-title":"Blood Press"},{"key":"BFhr2011178_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/cpt1974155443","volume":"15","author":"DR Taves","year":"1974","unstructured":"Taves DR . Minimization, a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974; 15: 443\u2013453.","journal-title":"Clin Pharmacol Ther"},{"key":"BFhr2011178_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1291\/hypres.24.475","volume":"24","author":"I Kuwajima","year":"2001","unstructured":"Kuwajima I, Kuramoto K, Ogihara T, Iimura O, Abe K, Saruta T, Ishii M, Hiwada K, Fujishima M, Fukiyama K, National Intervention Cooperative Study in Elderly Hypertensives (NICS-EH) Study Group. Tolerability and safety of a calcium channel blocker in comparison with a diuretic in the treatment of elderly patients with hypertension: secondary analysis of the NICS-EH. Hypertens Res 2001; 24: 475\u2013480.","journal-title":"Hypertens Res"},{"key":"BFhr2011178_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1291\/hypres.28.513","volume":"28","author":"JATOS Study Group:","year":"2005","unstructured":"JATOS Study Group:. The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res 2005; 28: 513\u2013520.","journal-title":"Hypertens Res"},{"key":"BFhr2011178_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/080370598437394","volume":"7","author":"J Mann","year":"1998","unstructured":"Mann J, Julius S, for the VALUE Trial Group: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial of Cardiovascular Events in Hypertension. Rationale and design. Blood Press 1998; 7: 176\u2013183.","journal-title":"Blood Press"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2011178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2011178","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2011178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:08:41Z","timestamp":1684429721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2011178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,17]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["BFhr2011178"],"URL":"https:\/\/doi.org\/10.1038\/hr.2011.178","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"type":"print","value":"0916-9636"},{"type":"electronic","value":"1348-4214"}],"subject":[],"published":{"date-parts":[[2011,11,17]]}}}